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SUMMARY
1. The aim of the present study was to compare and elucidate
the effects of a1-adrenoceptor (a1-AR) subtype-selective inverse
agonists on non-pregnant and late-pregnant rat cervical tone.
2. Cervical resistance was investigated in in vitro stretching
tests in the absence or presence of a1-AR subtype-selective inverse
agonists (WB 4101, AH 11110A and BMY 7378; all at 10-6 mol/L),
whereas the mRNA levels and density of the a1-AR subtypes
and the G-protein-activating effects of the inverse agonists were
determined by reverse transcription–polymerase chain reaction,
western blot and [35S]-GTPgS binding techniques, respectively.
3. The inverse agonists did not cause any change in resistance
in non-pregnant and 18-day-pregnant samples. WB 4101 increased
cervical resistance from Day 20, whereas AH 11110A had no
effect and BMY 7378 exhibited such an action only on Day 21.
Phenylephrine (10-4 mol/L) had no effect on cervical resistance
on Day 22. The mRNA levels and density of all a1-AR subtypes
were increased on Day 18, but no further changes were observed
after that. The [35S]-GTPgS binding studies revealed increased
G-protein activation of a1A-AR and a moderate G-protein acti-
vation of a1B- and a1D-AR. The effect of WB 4101 to increase
[35S]-GTPgS binding was blocked by pertussis toxin (50 ng/mL).
Phenylephrine caused a slight and significant decrease in the
amount of activated G-protein on Day 22.
4. The effects of inverse agonists on the a1A-AR can enhance
cervical resistance in the late-pregnant rat in vitro. This action
is mediated, at least in part, by a pertussis toxin-sensitive Gi-
protein. This effect of the a1A-AR inverse agonist WB 4101 may offer
a new therapeutic target in the prevention of premature labour.
Key words: a1-adrenoceptor inverse agonists, a1-adrenoceptor
subtypes, cervical resistance, cervical ripening, Gi-protein, pertussis
toxin, premature labour, [35S]-GTPgS binding.
INTRODUCTION
During pregnancy, the uterus undergoes dramatic changes. Although
the contractility of the corpus is steeply increased at term, the role of
the cervix shifts between two opposing functions. In the early phase of
pregnancy, the cervix has to resist tension and remain closed to protect
the fetus. However, at term, the cervical tissue is ripened in order to
accommodate stretching and delivery. The control of cervical softening
is a very complex process and is only partially understood. It is known
that progesterone,1 oestrogens,2 prostaglandins,3 cytokines4 and nitric
oxide5 all play essential roles in this process. It has also been clarified
that oestrogens and progesterone alter the density of adrenoceptors,6,7
but little is known about the role of these adrenoceptors in cervical
ripening. Early softening of the cervical tissue could be an important
step leading to preterm labour; accordingly, enhancement of cervical
resistance could be beneficial in the therapy of premature birth.
The density of a1-adrenoceptors in the rat myometrium was found
to be increased by the end of gestation, which suggests that these
adrenoceptors are involved in the increase of uterine contractility.8
Cloning and pharmacological data have revealed that a1-adrenoceptors
can be classified into three subtypes: a1A, a1B and a1D.9 The a1-
adrenoceptors play an important role in smooth muscle contraction
and hypertrophic growth.10,11 It has also been demonstrated that
a1-adrenoceptor antagonists can reduce contractions of isolated
pregnant uteri from the rat.12 However, no study has been performed
to investigate the effects of a1-adrenoceptor subtype-selective
antagonists on the resistance of pregnant cervical smooth muscle.
Characterization of the pharmacological properties of a1-
adrenoceptor ligands indicates that several antagonists appear to
have inverse agonist properties at these receptors. They are thought
to reduce the functional activity of the receptors below the baseline
activity observed in the absence of any ligand. Conversely, neutral
antagonists block receptors without affecting basal function. Many
a1-adrenoceptor subtype-selective antagonists, such as WB 4101
(a1A), AH 11110A (a1B) and BMY 7378 (a1D), are to be known inverse
agonists at concentrations of 10-8 to 10-5 mol/L.13–16
The aim of the present study was to investigate and elucidate the
effects of the a1-adrenoceptor subtype-selective inverse agonists
WB 4101, AH 11110A and BMY 7378 and the a1-adrenoceptor
agonist phenylephrine on isolated cervices from non-pregnant and
late-pregnant (Day 18–22) rats in vitro. Cervical resistance was
characterized by tissue extensibility to mechanical stretching. The
mRNA and protein levels of the a1-adrenoceptor subtypes were
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determined by using reverse transcription–polymerase chain
reaction (RT-PCR) and western blot analysis, respectively. The level
of G-protein activation coupled to a1-adrenoceptor subtypes was
investigated via the [35S]-guanosine-5¢-O-(3-thiotriphosphate) ([35S]-
GTPgS) binding assay.
METHODS
All experiments involving animals were performed with the approval of the
Hungarian Ethical Committee for Animal Research (registration no. IV/
1813-1/2002), which is in harmony with the control of the European Union.
Animal mating
Mature female (180–200 g) and male (240–260 g) Sprague-Dawley rats
were mated in a special mating cage. A metal door, which was movable by
a small electric engine, separated the rooms for the male and female animals.
A timer controlled the function of the engine. Because rats are usually active
at night, the separating door was opened before dawn. Within 4–5 h after
the possibility of mating, vaginal smears were taken from the female rats
and a sperm search was performed under a microscope at a magnification
of ¥1200. If the search proved positive, or if smear taking was impossible
because of an existing vaginal sperm plug, female rats were separated and
were regarded as first-day pregnant animals.
Measurement of cervical resistance
Cervical tissues were removed from non-pregnant and late-pregnant (gesta-
tional Day 18, 20, 21 or 22) rats. The cervix was defined as the least vascular
tissue with two parallel lumina between the uterine horns and the vagina.
The two cervical rings were separated and mounted, with their longitudinal
axis vertical, on hooks in an organ bath containing 10 mL de Jongh buffer
(composition (in mmol/L): NaCl 137; KCl 3; CaCl2 1; MgCl2 1; NaHCO3 12;
NaH2PO4 4; glucose 6, pH 7.4). The organ bath was maintained at 37∞C and
carbogen (95% O2 + 5% CO2) was bubbled through it. The lower sides of
the cervices were fixed to the bottom of the tissue holders in the organ
chambers, whereas the upper parts were hooked to gauge transducers (SG-
02; Experimetria, Budapest, Hungary). After mounting, the rings were allowed
to equilibrate for approximately 1 h before experiments were undertaken,
with a buffer change every 15 min. The initial tension was set to approxi-
mately 1.00 g.
The cervical resistance was investigated by gradually increasing the
tension in the tissues, as described previously.17 The changes in cervical
tension were followed with an online computer, using the SPEL Advanced
Isosys Data Acquisition System (Experimetria).
When drug effects were investigated, drugs were added to the organ bath
and the cervices were incubated for 5 min before stretching. The drugs
investigated were as follows: (i) 10-6 mol/L WB 4101 (10-8 to 10-4 mol/L,
with or without 10-6 mol/L phentolamine on Day 22), AH 11110A and
BMY 7378; or (ii) 10-4 and 10-6 mol/L phenylephrine, a selective a1-
adrenoceptor agonist, in the presence of 10-5 and 10-7 mol/L propranolol,
respectively, to inhibit stimulation of b2-adrenoceptors. Data were analysed
using Prism 4.00 (GraphPad Software, San Diego, CA, USA). Statistical
evaluations were made using anova and the Neuman–Keuls’ test.
When the effects of WB 4101 on basal (2 g precontraction at the beginning
of the incubation period) and precontracted (5 g precontraction at the begin-
ning of the incubation period) cervical tension were investigated, cumulative
concentration–response curves for WB 4101 were constructed over the
concentration range 10-8 to 10-4 mol/L for 22-day-pregnant cervices.
Reverse transcription–polymerase chain reaction studies
Cervical tissues from non-pregnant and pregnant animals were removed on
gestational Days 18, 20, 21 and 22 (n = 6 on each day), frozen in liquid
nitrogen and then stored at -70∞C until total RNA extraction.
Total cellular RNA was isolated by extraction with acid guanidinium
thiocyanate–phenol–chloroform according to the methods of Chomczynski
and Sacchi.18 After precipitation with isopropanol, RNA was washed three
times with ice-cold 75% ethanol and then dried. The pellet was resuspended
in 100 mL DNase- and RNase-free distilled water. The RNA concentrations
of the samples were determined from their absorbance at 260 nm.
The RNA (0.5 mg) was denatured at 70∞C for 5 min in a reaction mixture
containing 20 mmol/L oligo(dT) (Invitrogen, Paisley, UK), 20 U RNase
inhibitor (Invitrogen), 200 mmol/L dNTP (Sigma-Aldrich, Budapest, Hungary)
in 50 mmol/L Tris-HCl, pH 8.3, 75 mmol/L KCl and 5 mmol/L MgCl2 in a
final reaction volume of 20 mL. After the mixture had been cooled to 4∞C,
20 U M-MLV reverse transcriptase (Gibco, Paisley, UK) and 40 IU/mL
RNase H Minus (Invitrogen) was added and the mixture was incubated at
37∞C for 60 min.
The PCR was performed with 5 mL cDNA, 25 mL ReadyMix REDTaq
PCR reaction mix (Sigma-Aldrich) and 50 pmol of each of the forward and
reverse primers. The primer sequences used to amplify the a1A-adrenoceptor
were 5¢-GTA GCC AAG AGA GAA AGC CG-3¢ (for the forward primer) and
5¢-CAA CCC ACC ACG ATG CCC AG-3¢ (for the reverse primer); these
primers were anticipated to generate a 212 bp PCR product. For the rat a1B-
adrenoceptor cDNA, a 300 bp PCR product resulted with the forward primer
5¢-GCT CTT CTA CAT CCC GCT CG-3¢ and the reverse primer 5¢-AGG
GGA GCC AAC ATA AGA TGA-3¢. The primers for the a1D-adrenoceptor
were 5¢-CGT GTG CTC CTT CTA CCT ACC-3¢ (for the forward primer)
and 5¢-GCA CAG GAC GAA GAC ACC CAC-3¢ (for the reverse primer).19
A rat b-actin probe was used as an internal control in all samples.20 The PCR
was performed with a PCR Sprint thermal cycler (Hybaid, Ashford, UK), with
the following cycle parameters: after initial denaturation at 95∞C for 3 min,
the reactions were taken through 35 cycles of 1 min at 94∞C and annealing at
54∞C (a1B- and a1D-adrenoceptors) or 50∞C (a1A-adrenoceptor) for 1 min and
at 72∞C for 2 min. After the last cycle, incubation was continued for 10 min
at 72∞C, followed by lowering of the temperature to 4∞C. The RT-PCR prod-
ucts were separated on 2% agarose gels, stained with ethidium bromide and
photographed under an ultraviolet transilluminator. Quantitative analysis was
performed by densitometric scanning of the gel using a Kodak EDAS290
(Csertex, Budapest, Hungary). For statistical evaluations, data were analysed
by anova with the Neuman–Keuls’ post test.
Western blot analysis
In these analyses, 20 mg protein/well was subjected to electrophoresis on
10% sodium dodecyl sulphate polyacrylamide gels in Series Standard Dual
Cooled Units (Bio-Rad, Budapest, Hungary). Proteins were transferred
from gels to nitrocellulose membranes (Scheicher and Schuell, Darmstadt,
Germany) using a semidry blotting technique (Bio-Rad). Membranes were
blocked with 5% non-fat dry milk in Tris saline buffer (50 mmol/L Tris,
pH 7.4, 200 mmol/L NaCl) containing 0.1% Tween overnight at 4∞C. After
washing, blots were incubated for 1 h on a shaker at room temperature with
a1A-, a1B- and a1D-adrenoceptor and b-actin polyclonal antibodies (1 : 200;
Santa Cruz Biotechnology, Santa Cruz, VA, California) in blocking buffer.
Antibody binding was detected with a Western Breeze Chromogenic
Western blot immunedetection kit (Invitrogen). Quantitative analysis was
performed by densitometric scanning of the gel with a Kodak EDAS290
(Csertex). For statistical evaluations, data were analysed by anova with the
Neuman–Keuls’ post test.
[35S]-GTPgS binding assay
Rat cervix membrane fractions (approximately 10 mg protein/sample) were
incubated at 30∞C for 60 min in Tris-EGTA buffer (composition (in mmol/L):
Tris-HCl 50; EGTA 1; MgCl2 3; NaCl 100, pH 7.4) containing 20 MBq/
0.05 mL [35S]-GTPgS (0.05 nmol/L) and increasing concentrations (10-10 to
10-6 mol/L) of WB 4101, AH 11110A, BMY 7378 or phenylephrine in the
presence of excess GDP (30 pmol/L) in a final volume of 1 mL, as described
by Sim et al.21 and Traynor and Nahorski22 with slight modifications. The Gi-
protein activating effect of WB 4101 was measured in the presence of 500 ng
pertussis toxin. Non-specific binding was determined with 10 mmol/L
44 Z Kolarovszki-Sipiczki et al.
© 2007 The Authors
Journal compilation © 2007 Blackwell Publishing Asia Pty Ltd
GTPgS and subtracted. Bound and free [35S]-GTPgS were separated by
vacuum filtration through Whatman GF/B filters (Whatman, Dassel, Germany)
with a Millipore manifold (Millipore, Budapest, Hungary). Filters were washed
with three times with 5 mL ice-cold buffer and the radioactivity of the dried
filters was determined in a toluene-based scintillation cocktail in a Wallac
1409 scintillation counter (Turku, Finland). The percentage stimulation caused
by WB 4101 was plotted against the concentration of the drug. Concentration–
response curves were fitted and the concentrations eliciting the maximum
effect (Emax) were calculated and analysed statistically using anova and the
Neuman–Keuls’ test.
RESULTS
In isolated organ bath studies, we found no extensibility of the non-
pregnant cervices. The pregnant cervical resistance decreased
continuously from Day 18 towards term, reaching minimum values
on Days 21 and 22 (Fig. 1). Compared with non-treated cervices,
WB 4101 had no effect on non-pregnant and 18-day-pregnant
tissues, but increased cervical resistance from Day 20 to Day 22.
Fig. 2 Changes in mRNA levels of a1-adrenoceptor (AR) subtypes in non-pregnant and 18-day pregnant rat cervices. (a) a1A-Adrenoceptors; (b) a1B-
adrenoceptors; (c) a1D-adrenoceptors. Each band contains RNA from the cervix of one animal. The reverse transcription–polymerase chain reaction products
were stained with ethidium bromide and photographed under an ultraviolet transilluminator. Semiquantitative analysis was performed by densitometric scanning
of the gel and result are expressed as the ratio of the optical densities of a1-adrenoceptor/GAPDH. ***P < 0.001 compared with non-preganant samples.
Fig. 3 Changes in a1-adrenoceptor (AR) levels in non-pregnant and 18-day pregnant rat cervices (n = 6). The 51.5, 70, 72 and 42 kDa western blot products
are the a1A-adrenoceptor, a1B-adrenoceptor, a1D-adrenoceptor and b-actin, respectively. (a) a1A-Adrenoceptors; (b) a1B-adrenoceptors; (c) a1D-adrenoceptors.
Samples were subjected to gel electrophoresis on a 10% polyacrylamide gel. Antibody binding was detected with an enhanced chemiluminescence detection
system and expressed as a ratio of the optical densities of a1-adrenoceptor/b-actin. ***P < 0.001 compared with non-preganant samples.
Fig. 1 Effects of the a1A-adrenoceptor subtype-selective antagonist 10-6 mol/L
WB 4101 () on the cervical resistance of non-pregnant and late-pregnant
rat cervices in vitro (n = 6). Resistance is expressed as the slope of the
regression lines fitted to the stress–strain curves. (), slopes from non-
treated (control) cervices. *P < 0.05 compared with resistance of the control
sample for the same day.
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This effect was most marked on Days 21 and 22 (Fig. 1). AH 11110A
and BMY 7378 had no effect on the cervical resistance in vitro,
except on Day 21, when BMY 7378 treatment resulted in a weak
(but significant) increase in cervical resistance (data not shown).
We demonstrated the expression of a1-adrenoceptor subtype mRNA
in non-pregnant and late-pregnant rat cervices using RT-PCR. a1B-
Adrenoceptors were not present in non-pregnant samples, whereas
low levels of a1A- and a1D-adrenoceptor mRNA were detected. On
Day 18, there were increases in the mRNA levels of all cervical a1-
adrenoceptor subtypes and no further changes were detected up until
the end of pregnancy (Fig. 2). The results of western blot analysis
at the level of receptor protein expression were in agreement with
the PCR results (Fig. 3).
In the GTPgS binding studies, WB 4101 caused a stimulation of
[35S]-GTPgS binding compared with basal values up to Day 22 of
pregnancy (Fig. 4). AH 11110A did not activate the G-proteins,
whereas BMY 7378 significantly increased [35S]-GTPgS binding
only on Day 21 by 93.5% (data not shown).
The effect of WB 4101 in increasing cervical resistance concen-
tration dependent over the range 10-8 to 10-4 mol/L on Day 22. This
concentration–response curve was shifted to the right in the presence
of 10-6 mol/L phentolamine (Fig. 5). WB 4101 over the concentration
range 10-8 to 10-4 mol/L had no effect on basal and precontracted
cervical muscle tone on Day 22. Phenylephrine, a non-selective a1-
adrenoceptor agonist, had no effect on the cervical resistance on Day
22 at concentrations of 10-6 and 10-4 mol/L.
Phenylephrine caused a slight and significant decrease in the amount
of activated G-protein on Day 22. The effect of WB 4101 in increasing
[35S]-GTPgS binding was blocked by pertussis toxin (Fig. 6).
DISCUSSION
The harmonized co-operation between the cervix and the myometrium
results in safe delivery. Because premature cervical dilation can
contribute to preterm birth of the fetus,23 compounds that increase
cervical resistance could be beneficial in the therapy of premature
complications. Although a1-adrenoceptor inverse agonists are known
to decrease uterine contractility,28,29 no reliable information is available
concerning their action on the cervix.
Fig. 4 Changes in [35S]-GTPgS binding following treatment with the a1A-
adrenoceptor subtype-selective inverse agonist WB 4101 in non-pregnant
and late-pregnant rat cervical membranes. The percentage stimulation caused
by the compound was plotted against the concentration of the drug. Basal
refers to the value of [35S]-GTPgS binding in the absence of WB 4101. Data
are given as the percentage stimulation over basal (non-stimulated taken as
100%). The rising curves indicate increased G-protein activation following
the addition of WB 4101 to the cervical membrane preparations. (),
Day 22; (), Day 21; (), Day 20; (), Day 18; (), non-pregnant.
Fig. 5 Effect of phentolamine on the effect of WB 4101 in increasing
cervical resistance in 22-day-pregnant cervices. The effect of WB 4101 on
cervical resistance was expressed as the slope difference, calculated by
subtraction of the average slope (0.7867) for non-treated samples from that
for treated samples. The drug elicited a concentration-dependent increase in
slope difference (). True antagonists, such as phentolamine, which is an
a1-adrenoceptor antagonist, can antagonize the effects of inverse agonistic
drugs. In the presence of 10-6 mol/L phentolamine (), the slope-difference
curve was shifted to the right, without a significant change in its maximum
value, suggesting an a-adrenoceptor-mediated action of WB 4101 on the
cervical resistance.
Fig. 6 Changes in [35S]-GTPgS binding following treatment with
phenylephrine () and WB 4101, with () and without () pertussis toxin,
in non-pregnant and late-pregnant rat cervical membranes. The percentage
stimulation caused by the compounds was plotted against the concentration
of the drug. Basal refers to the value of [35S]-GTPgS binding without the
substance. Data are given as the percentage stimulation over basal (non-
stimulated taken as 100%). The a1-adrenoceptor agonist phenylephrine, at
a high concentration, slightly and significantly decreased the activated G-
protein level on Day 22. The effect of WB 4101 in increasing [35S]-GTPgS
binding was blocked by 50 ng/mL pertussis toxin.
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In the present study, of the three inverse agonists examined, only
WB 4101, an a1A-adrenoceptor subtype-selective agonist, elicited a
considerable increase in cervical resistance to mechanical stretching
in the late-pregnant rat cervix. The a1B-adrenoceptor subtype-selective
agonist AH 11110A had no effect on cervical resistance, whereas
the effects of BMY 7378, an a1D-adrenoceptor-selective agonist, to
increase cervical resistance were manifested on Day 21 only.
To clarify the differences in the effects of the different a1-
adrenoceptor inverse agonists on cervical tone, we first determined
the presence and changes in a1-adrenoceptor mRNA and protein
expression using RT-PCR and western blot analysis, respectively.
Receptor synthesis and expression were found to be elevated in late-
pregnant rat cervices compared with non-pregnant samples, but no
differences were detected between levels on the investigated days of
pregnancy. This elevation itself partially explains the inefficiency of
WB 4101 in the non-pregnant cervix, but gives no explanation for
the inefficiency of AH 11110A and BMY 7378 on both non-pregnant
and pregnant cervices.
For further clarification, we performed [35S]-GTPgS binding studies.
a1-Adrenoceptors are mainly coupled to Gq/11-protein and mainly
activate phospholipase C, thereby increasing the levels of inositol
1,4,5-triphosphate and 1,2-diacylglycerol.24,25 Conversely, it has been
proven that these receptors can be coupled to G0- or Gi-proteins in
some cases.26,27 The [35S]-GTPgS binding assay measures the level of
G-protein activation following antagonist occupation of the G-protein-
coupled receptor. This method detects the functional consequence of
receptor occupancy in one of the earliest receptor-mediated events.
In the assay, [35S]-GTPgS replaces endogenous GTP and binds to
the a-subunit of the G-protein (Ga). The g-thiophosphate bond is
resistant to the hydrolysis of Ga by GTPase. Accumulation of the
labelled Ga subunits can be measured by counting the amount of
[35S] incorporated.30 This method is most useful for investigating
activation of Gi-coupled receptors.
In the present studies of a1A-adrenoceptor occupancy, WB 4101
resulted in a moderate increase in [35S]-GTPgS binding compared
with basal values in pregnant samples, whereas no effect was detected
in non-pregnant cervices. Stimulation of a1B- and a1D-adrenoceptors
was found to have no and a time-dependent effect in the [35S]-GTPgS
binding assay, respectively. In subsequent experiments, the effects
of WB 4101 were investigated further, whereas no further investi-
gations were performed for the other two inverse agonists.
The smooth muscle content of the cervix is known to be quite low
and is further reduced by pregnancy induced apoptosis.31 Therefore,
the possibility that the effect of WB 4101 is not mediated by a1A-
adrenoceptors was also considered. In order to create a concentration–
response curve, 22-day-pregnant cervical samples were used because
the difference in cervical resistance between non-treated and
10-6 mol/L WB 4101-treated cervices was highest on this day. In
organ bath studies, we proved that the effect of WB 4101 in increas-
ing cervical resistance is concentration dependent and that this effect
can be antagonized by the non-selective a-adrenoceptor antagonist
phentolamine. This is a further evidence for the inverse agonist
property of WB 4101, because true antagonists (e.g. phentolamine)
can antagonize the effects of inverse agonists.32
WB 4101 is highly selective for a1A-adrenoceptors; accordingly,
it can be concluded that the effect of WB 4101 in increasing cervical
resistance is predominantly related to these receptors. However, WB
4101 proved ineffective on basal cervical muscle tone when gradual
stretching was omitted. These results suggest that WB 4101 increases
the resistance of the pregnant cervix against incremental stretching,
but apparently does not affect basal smooth muscle tone.
Drugs that behave as inverse agonists commonly decrease both
[35S]-GTPgS binding and G-protein activation, whereas real agonists
elicit the opposite effects.30 Conversely, we have demonstrated recently
in [35S]-GTPgS binding studies that the b2-adrenoceptor agonist
terbutaline behaves as an inverse agonist in the pregnant rat cervix.17
Accordingly, it may be concluded that the G-protein-activating
properties of agonists and inverse agonists may be reversed in the
pregnant rat cervix.
In order to acquire more evidence in this respect, the effect of a
real agonist was also tested in our system. Phenylephrine had no
effect on cervical resistance in vitro, but at a high concentration, it
decreased the activated G-protein level. These results support our
theory that the activation of G-proteins in the cervical adrenergic
system by an agonist or an inverse agonist is controlled in an opposite
way compared with that in the myometrium. The ineffectiveness of
phenylephrine on cervical resistance can be explained by its very
weak G-protein-moderating action.
It is known that the catalytic A subunit (S1) of pertussis-toxin
(PTX) transfers the ADP ribosyl moiety of nicotinamide adenine
dinucleotide phosphate (NAD) to the membrane-bound regulatory
protein Gi, which normally inhibits adenylate cyclase. This inhibitory
action of PTX is special for the Gi-protein and enables distinction
of the different G-protein-mediated signal transduction pathways. In
the present study, PTX inhibited the effect of WB 4101 in increasing
[35S]-GTPgS binding (and, thus, G-protein activation); consequently,
we assume that the effects of WB 4101 are connected, at least partially,
with PTX-sensitive G-proteins, supposedly Gi-proteins, although an
interaction with the Gq/11-protein (Gq/11) cannot be excluded. We
therefore presume that these changes in the level of activated Gi
and/or Gq/11 mediate an intracellular process that is not sufficient to
cause a change in basal smooth muscle tone, but can provide a stronger
resistance against stretching forces. This effect may offer new perspec-
tives in the therapy of preterm labour. Although the a1A-adrenoceptor
inverse agonist WB 4101 is not yet used in obstetric practice, its ability
to increase cervical resistance may be applicable in the prevention
or treatment of early dilation of the pregnant cervix.
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